Aquestive Therapeutics

About Aquestive Therapeutics

Aquestive Therapeutics is a specialty pharmaceutical company that focuses on developing and commercializing innovative treatments for patients with complex medical conditions. The company operates primarily in the healthcare and pharmaceutical markets, targeting patients, caregivers, and healthcare providers as its main clients.

Aquestive's core business revolves around its proprietary PharmFilm® technology, which allows for the delivery of medications via soluble films that dissolve when placed inside the cheek. This method offers a convenient and effective alternative to traditional pills and injections, particularly for patients who have difficulty swallowing or require rapid onset of medication. One of their notable products is Libervant, a buccal film formulation of diazepam designed for the acute treatment of seizure clusters in epilepsy patients aged 12 and older.

The company generates revenue through the development, licensing, and commercialization of its proprietary drug delivery technologies and products. Aquestive partners with other pharmaceutical companies to co-develop new treatments, which allows them to earn licensing fees, milestone payments, and royalties on product sales. Additionally, they market and sell their own branded products directly to healthcare providers and patients.

Aquestive operates in a highly regulated market, navigating the complexities of clinical trials, regulatory approvals, and market access strategies to bring their innovative treatments to patients in need. Their business model is built on leveraging their unique drug delivery technology to create differentiated products that address unmet medical needs, thereby providing value to both patients and shareholders.